To the Editor We note the review by Heyward et al1 critiquing the US Food and Drug Administration’s (FDA’s) oversight of the extended-release/long-acting (ER/LA) opioid analgesic Risk Evaluation and Mitigation Strategy (REMS). The authors’ conclusions reiterate those that the FDA presented at a public advisory committee meeting on May 3 and 4, 2016, regarding the assessment of the ER/LA REMS, a voluntary continuing education (CE) program.2 At this meeting, there was discussion of how this REMS was 1 among many educational activities and other interventions being implemented at local, state, and federal levels to address the opioid crisis.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Auth D, Staffa J, LaCivita C. Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program. JAMA Intern Med. 2020;180(6):915–916. doi:10.1001/jamainternmed.2020.1260
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: